The QMN Weekly Bulletin
Pharmaceuticals / Regulatory Affairs / Submissions and Approvals

Actavis Gets Complete Response Letter for Transdermal Contraceptive Patch

Jan. 3, 2014
Actavis’ NDA for a progestin-only transdermal contraceptive patch has been turned down by the FDA, according to the company. The rejection comes about 10 months after the NDA was filed.
Drug Daily Bulletin